Novavax's COVID-19 Vaccine Gets Complete Approval From European Commission
Portfolio Pulse from Vandana Singh
Novavax's COVID-19 vaccine, Nuvaxovid, has received full approval from the European Commission for use in individuals aged 12 and older, and as a booster dose in adults aged 18 and older. The vaccine is authorized for use in over 40 markets worldwide but has not yet been approved by the FDA. Novavax's shares are down 2.85% at $7.15.
July 06, 2023 | 5:25 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Novavax's COVID-19 vaccine has received full approval from the European Commission, potentially increasing its market reach. However, the company's shares are currently down.
The full approval of Novavax's COVID-19 vaccine by the European Commission is a significant milestone for the company, potentially increasing its market reach and revenues. However, the lack of FDA approval and the current decrease in the company's share price may offset any potential short-term gains.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100